FOLD plans to submit a new drug application to FDA for the oral precision medicine migalastat for Fabry disease. The stock is jumping on the news.
We are not recommending buying FOLD here but it can be part of a basket on a pullback as discussed below.
Based on questions you are asking us, we are republishing the prior post here:
INTELLIGENCE: SEVEN POTENTIAL BIOTECH BUYOUT TARGETS IN WAKE OF ARIA BUYOUT
For us to recommend, a stock must pass at least four of the six screens. We prefer a stock to meet all six screens.